Biogen tabs veteran pharma leader Viehbacher as next CEO
Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm.
The company said Thursday that the 62-year-old Viehbacher will become president and CEO on Monday, replacing Michel Vounatsos.
Biogen said in May that Vounatsos would leave as soon as the company found a successor. The announcement came less than a year after Biogen introduced the first new Alzheimer’s drug in nearly two decades at a price — about $56,000 annually — that stunned doctors and patients.
Biogen later slashed that price, but the drug's launch has been hampered by tight coverage restrictions imposed by the federal government’s Medicare program and a hesitancy from doctors to prescribe it. By last spring, Biogen had decided to eliminate most of its spending on a drug that analysts once thought would generate billions of dollars in annual revenue.
Aduhelm brought in $1.6 million in sales during the recently completed third quarter, during which Biogen did better than analysts expected, helped in part by a cost-cutting program. Biogen’s product portfolio also includes the multiple sclerosis treatment Tecfidera and Spinraza, which is used to treat a rare spinal disorder in children.
Viehbacher served six years as CEO of Sanofi before the French drugmaker sacked him in 2014.
The company’s share price more than doubled during Viehbacher’s tenure, which was marked by a $20-billion takeover of U.S. biotech firm Genzyme. But Sanofi’s chairman said in 2014 that the board unanimously decided to fire him over dissatisfaction with his management style and handling of some parts of the business.
Before Sanofi, Viehbacher served as an executive with British drugmaker GlaxoSmithKline. More recently, he co-founded the health care investment fund Gurnet Point Capital, Biogen said.
Shares of Cambridge, Massachusetts-based Biogen Inc. climbed more than 2% to $289.75 Thursday morning while broader indexes also jumped.
___
Follow Tom Murphy on Twitter: @thpmurphy